Literature DB >> 16909199

A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2.

S Cébe Suarez1, M Pieren, L Cariolato, S Arn, U Hoffmann, A Bogucki, C Manlius, J Wood, K Ballmer-Hofer.   

Abstract

The development of functional blood and lymphatic vessels requires spatio-temporal coordination of the production and release of growth factors such as vascular endothelial growth factors (VEGFs). VEGF family proteins are produced in multiple isoforms with distinct biological properties and bind to three types of VEGF receptors. A VEGF-A splice variant, VEGF-A(165)b, has recently been isolated from kidney epithelial cells. This variant is identical to VEGF-A(165) except for the last six amino acids encoded by an alternative exon. VEGF-A(165)b and VEGF-A(165) bind VEGF receptors 1 and 2 with similar affinity. VEGF-A(165)b elicits drastically reduced activity in angiogenesis assays and even counteracts signaling by VEGF-A(165). VEGF-A(165)b weakly binds to heparan sulfate and does not interact with neuropilin-1, a coreceptor for VEGF receptor 2. To determine the molecular basis for altered signaling by VEGF-A(165)b we measured VEGF receptor 2 and ERK kinase activity in endothelial cells in culture. VEGF-A(165) induced strong and sustained activation of VEGF receptor 2 and ERK-1 and -2, while activation by VEGF-A(165)b was only weak and transient. Taken together these data show that VEGF-A(165)b has attenuated signaling potential through VEGF receptor 2 defining this new member of the VEGF family as a partial receptor agonist.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16909199     DOI: 10.1007/s00018-006-6254-9

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  89 in total

Review 1.  VEGFA splicing: divergent isoforms regulate spermatogonial stem cell maintenance.

Authors:  Kevin M Sargent; Debra T Clopton; Ningxia Lu; William E Pohlmeier; Andrea S Cupp
Journal:  Cell Tissue Res       Date:  2015-11-09       Impact factor: 5.249

2.  Inhibitory effects of Semaphorin 3F as an alternative candidate to anti-VEGF monoclonal antibody on angiogenesis.

Authors:  Gamze Tan
Journal:  In Vitro Cell Dev Biol Anim       Date:  2019-08-16       Impact factor: 2.416

3.  VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop.

Authors:  Asma Boudria; Cherine Abou Faycal; Tao Jia; Stephanie Gout; Michelle Keramidas; Chloé Didier; Nicolas Lemaître; Sandra Manet; Jean-Luc Coll; Anne-Claire Toffart; Denis Moro-Sibilot; Corinne Albiges-Rizo; Véronique Josserand; Eva Faurobert; Christian Brambilla; Elisabeth Brambilla; Sylvie Gazzeri; Beatrice Eymin
Journal:  Oncogene       Date:  2018-09-07       Impact factor: 9.867

4.  Mechanisms regulating angiogenesis underlie seasonal control of pituitary function.

Authors:  Jennifer Castle-Miller; David O Bates; Domingo J Tortonese
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-07       Impact factor: 11.205

5.  Urothelial expression of neuropilins and VEGF receptors in control and interstitial cystitis patients.

Authors:  Ricardo Saban; Marcia R Saban; Julie Maier; Ben Fowler; Mark Tengowski; Carole A Davis; Xue-Ru Wu; Daniel J Culkin; Paul Hauser; Joseph Backer; Robert E Hurst
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-24

Review 6.  Therapeutic potential of manipulating VEGF splice isoforms in oncology.

Authors:  Emma S Rennel; Steven J Harper; David O Bates
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

7.  VEGF in the lung: a role for novel isoforms.

Authors:  Julia Varet; Samantha K Douglas; Laura Gilmartin; Andrew R L Medford; David O Bates; Steven J Harper; Ann B Millar
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-03-12       Impact factor: 5.464

Review 8.  The role of VEGF 165b in pathophysiology.

Authors:  Maria Peiris-Pagès
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

9.  HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165.

Authors:  Sophie Lambert; Manuella Bouttier; Roger Vassy; Michel Seigneuret; Cari Petrow-Sadowski; Sébastien Janvier; Nikolaus Heveker; Francis W Ruscetti; Gérard Perret; Kathryn S Jones; Claudine Pique
Journal:  Blood       Date:  2009-03-06       Impact factor: 22.113

10.  VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo.

Authors:  E S Rennel; A H R Varey; A J Churchill; E R Wheatley; L Stewart; S Mather; D O Bates; S J Harper
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.